City Therapeutics
City Therapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered at 399 Binney Street in Kendall Square, Cambridge, Massachusetts, founded in 2024 by pioneers of RNA interference including John Maraganore, Phillip Zamore, Kotaro Nakanishi, Yukihide Tomari and Mark Keating. The company engineers next-generation RNAi trigger molecules — including its proprietary cleavage-inducing tiny (city) RNAs — and pairs them with precision targeting ligands designed to deliver siRNAs beyond the liver into ocular, CNS and other extrahepatic tissues. Its pipeline includes CITY-FXI, a Factor XI-targeting candidate for thromboembolic disease, and CITY-RBP4 for Stargardt disease and geographic atrophy, alongside undisclosed hepatic, ocular and CNS programs. City Therapeutics raised a $135M Series A in October 2024 and a $99.5M Series B in June 2026, and holds research collaborations with Biogen and Bausch + Lomb. City Therapeutics publishes no public developer program, API, or machine-readable interface; it is catalogued here as a company profile only.
City Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Therapeutics.
City Therapeutics’ developer surface includes product news, engineering blog, and 18 more developer resources.
Kin Score
Terms of Service 1
What its API terms permit and prohibit, quoted from its own page.
Privacy & Data 1
Its role, the data it processes, retention and transfers, quoted from its own privacy page.
Eligibility 1
Who may sign up and where, quoted from its own terms.
City Therapeutics
2 quoted statements, read from City Therapeutics's own page on 2026-11-09.
ELIGIBILITYAI Preferences 1
Its stance on AI training, inference and agents, quoted from its own pages.
Data License 1
How its data and outputs may be reused, quoted from its own terms.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Documentation 1
Reference material describing how the API behaves
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 4
Pricing, plans, and the legal terms of use
Company 7
The organization behind the API
Scroll for all 7
Other 5
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.